Company / PP&E (Net)
Corbus Pharmaceuticals Holdings, Inc. PP&E (Net) History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.6M
FY2022
5-year range
$1.6M / $5.1M
FY2018-FY2022
Trend
-32.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $5M in FY2019 to $2M in FY2022.
Based on SEC 10-K filings.
$2M in FY2022 with a 5-year CAGR of +2.4%.
Declined from $4M to $2M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -31.8%
- 5-Year CAGR
- +2.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Corbus Pharmaceuticals Holdings, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +2.4%, indicating consistent growth.
- In FY2022, pp&e (net) decreased 32.6% year-over-year.
- Peak pp&e (net) was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | $1.6M | -32.6% |
| FY2021 | $2.4M | -41.2% |
| FY2020 | $4.1M | -20.0% |
| FY2019 | $5.1M | +87.9% |
| FY2018 | $2.7M | +88.8% |
| FY2017 | $1.4M | +229.2% |
| FY2016 | $435.3K | +250.6% |
| FY2015 | $124.1K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026